Key Data Updates in HER2+ Breast Cancer from SABCS 2023

home / data-dialogue-with-the-oncology-brothers / key-data-updates-in-her2-breast-cancer-from-sabcs-2023

Following SABCS 2023, Daniel Stover, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss key clinical trial data updates in HER2+ Breast Cancer.

Daniel Stover, MD; Rahul Gosain, MD; and Rohit Gosain, MD, presenting slides

EP. 1: Sub-Analysis from APHINITY on Adjuvant Pertuzumab and Trastuzumab in HER2+ Breast Cancer

Rohit Gosain, MD;Rahul Gosain, MD;Daniel G. Stover, MD
January 11th 2024

Following SABCS 2023, Daniel Stover, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss the benefit of adjuvant pertuzumab and trastuzumab according to ER and HER2 expression in patients with HER2+ breast cancer.

Daniel Stover, MD; Rohit Gosain, MD; and Rahul Gosain, MD, presenting slides

EP. 2: Update from KATHERINE on Adjuvant T-DM1 for Residual Invasive HER2+ Early Breast Cancer

Rohit Gosain, MD;Rahul Gosain, MD;Daniel G. Stover, MD
January 11th 2024

Medical oncologists discuss the recent update from the KATHERINE trial investigating adjuvant T-DM1 (trastuzumab emtansine) following neoadjuvant chemotherapy in patients with residual invasive HER2+ early breast cancer.

Daniel Stover, MD; Rohit Gosain, MD; and Rahul Gosain, MD, presenting slides

EP. 3: HER2CLIMB-02: Tucatinib and T-DM1 for Previously Treated HER2+ Metastatic Breast Cancer

Rohit Gosain, MD;Rahul Gosain, MD;Daniel G. Stover, MD
January 11th 2024

Daniel Stover, MD, and the Oncology Brothers review results from HER2CLIMB-02, a randomized, double-blind phase 3 trial of tucatinib and T-DM1 in patients with previously treated HER2+ metastatic breast cancer.

Rahul Gosain, MD, and Rohit Gosain, MD, the Oncology Brothers

EP. 4: Key Takeaways from SABCS 2023 in HER2+ Breast Cancer

Rohit Gosain, MD;Rahul Gosain, MD;Daniel G. Stover, MD
January 11th 2024

Following their review of clinical trial data presented at SABCS 2023, the Oncology Brothers discuss their key takeaways on recent updates in HER2+ breast cancer.